Epoch Investment Partners Inc. Increases Stake in Bristol Myers Squibb Company $BMY

Posted by Brian Himes on Jul 25th, 2026

Epoch Investment Partners Inc. lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 4.7% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,228,074 shares of the biopharmaceutical company’s stock after purchasing an additional 55,319 shares during the period. Epoch Investment Partners Inc.’s holdings in Bristol Myers Squibb were worth $74,483,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Swiss RE Ltd. purchased a new position in Bristol Myers Squibb in the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Bayban purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.9%

Shares of NYSE BMY opened at $62.05 on Friday. The business has a 50-day moving average price of $57.49 and a 200 day moving average price of $58.03. The stock has a market cap of $126.70 billion, a PE ratio of 17.43, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title
Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title
Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title
Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title
Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title

Analysts Set New Price Targets

Several equities analysts recently commented on BMY shares. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Bank of America lowered their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $61.25.

Read Our Latest Analysis on BMY

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.